Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults
ABSTRACT: Objectives: In this study, we aimed to investigate the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent (aTIV) and non-adjuvanted quadrivalent (QIVe) egg-based standard-dose vaccines against severe laboratory-confirmed influenza. Methods: This test-negative case-contr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S120197122200580X |
| _version_ | 1811196729623576576 |
|---|---|
| author | Alexander Domnich Donatella Panatto Elena Pariani Christian Napoli Maria Chironna Ilaria Manini Caterina Rizzo Andrea Orsi Giancarlo Icardi |
| author_facet | Alexander Domnich Donatella Panatto Elena Pariani Christian Napoli Maria Chironna Ilaria Manini Caterina Rizzo Andrea Orsi Giancarlo Icardi |
| author_sort | Alexander Domnich |
| collection | DOAJ |
| description | ABSTRACT: Objectives: In this study, we aimed to investigate the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent (aTIV) and non-adjuvanted quadrivalent (QIVe) egg-based standard-dose vaccines against severe laboratory-confirmed influenza. Methods: This test-negative case-control study was conducted in a hospital setting during four recent Italian influenza seasons (from 2018/19 to 2021/22). The clinical outcome was severe acute respiratory infection (SARI) with laboratory confirmation diagnosed among subjects aged ≥65 years. rVE of aTIV versus QIVe was estimated through propensity score matching followed by logistic regression. Results: The influenza virus circulated to a significant extent only during the 2018/19 and 2019/20 seasons. The final population included 512 vaccinated older adults, of which 83 were cases and 429 were test-negative controls. aTIV and QIVe users differed substantially from the point of view of several baseline characteristics. The propensity score adjusted rVE of aTIV vs QIVe was 59.2% (95% CI: 14.6%, 80.5%), 54.7% (95% CI: -28.7%, 84.0%) and 56.9% (95% CI: -7.8%, 82.8%) against any influenza, A(H1N1)pdm09 and A(H3N2), respectively. Conclusion: aTIV was more effective than QIVe in preventing laboratory-confirmed SARI. The benefits of aTIV may be obscured by confounding indication. |
| first_indexed | 2024-04-12T01:03:54Z |
| format | Article |
| id | doaj.art-d59f1e22c44344a683bb1fe4c54d3775 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-12T01:03:54Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-d59f1e22c44344a683bb1fe4c54d37752022-12-22T03:54:20ZengElsevierInternational Journal of Infectious Diseases1201-97122022-12-01125164169Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adultsAlexander Domnich0Donatella Panatto1Elena Pariani2Christian Napoli3Maria Chironna4Ilaria Manini5Caterina Rizzo6Andrea Orsi7Giancarlo Icardi8Hygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy; Corresponding author.Department of Health Sciences, University of Genoa, Genoa, Italy; Interuniversity Research Center on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, ItalyInteruniversity Research Center on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, ItalySant'Andrea Hospital, University La Sapienza, Rome, ItalyInterdisciplinary Department of Medicine, University of Bari, Bari, ItalyInteruniversity Research Center on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy; Department of Molecular and Developmental Medicine, University of Siena, Siena, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, ItalyHygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy; Department of Health Sciences, University of Genoa, Genoa, Italy; Interuniversity Research Center on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, ItalyHygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy; Department of Health Sciences, University of Genoa, Genoa, Italy; Interuniversity Research Center on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, ItalyABSTRACT: Objectives: In this study, we aimed to investigate the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent (aTIV) and non-adjuvanted quadrivalent (QIVe) egg-based standard-dose vaccines against severe laboratory-confirmed influenza. Methods: This test-negative case-control study was conducted in a hospital setting during four recent Italian influenza seasons (from 2018/19 to 2021/22). The clinical outcome was severe acute respiratory infection (SARI) with laboratory confirmation diagnosed among subjects aged ≥65 years. rVE of aTIV versus QIVe was estimated through propensity score matching followed by logistic regression. Results: The influenza virus circulated to a significant extent only during the 2018/19 and 2019/20 seasons. The final population included 512 vaccinated older adults, of which 83 were cases and 429 were test-negative controls. aTIV and QIVe users differed substantially from the point of view of several baseline characteristics. The propensity score adjusted rVE of aTIV vs QIVe was 59.2% (95% CI: 14.6%, 80.5%), 54.7% (95% CI: -28.7%, 84.0%) and 56.9% (95% CI: -7.8%, 82.8%) against any influenza, A(H1N1)pdm09 and A(H3N2), respectively. Conclusion: aTIV was more effective than QIVe in preventing laboratory-confirmed SARI. The benefits of aTIV may be obscured by confounding indication.http://www.sciencedirect.com/science/article/pii/S120197122200580XInfluenzaInfluenza vaccinesAdjuvanted influenza vaccineVaccine effectivenessOlder adults |
| spellingShingle | Alexander Domnich Donatella Panatto Elena Pariani Christian Napoli Maria Chironna Ilaria Manini Caterina Rizzo Andrea Orsi Giancarlo Icardi Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults International Journal of Infectious Diseases Influenza Influenza vaccines Adjuvanted influenza vaccine Vaccine effectiveness Older adults |
| title | Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults |
| title_full | Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults |
| title_fullStr | Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults |
| title_full_unstemmed | Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults |
| title_short | Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults |
| title_sort | relative effectiveness of the adjuvanted vs non adjuvanted seasonal influenza vaccines against severe laboratory confirmed influenza among hospitalized italian older adults |
| topic | Influenza Influenza vaccines Adjuvanted influenza vaccine Vaccine effectiveness Older adults |
| url | http://www.sciencedirect.com/science/article/pii/S120197122200580X |
| work_keys_str_mv | AT alexanderdomnich relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT donatellapanatto relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT elenapariani relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT christiannapoli relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT mariachironna relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT ilariamanini relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT caterinarizzo relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT andreaorsi relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults AT giancarloicardi relativeeffectivenessoftheadjuvantedvsnonadjuvantedseasonalinfluenzavaccinesagainstseverelaboratoryconfirmedinfluenzaamonghospitalizeditalianolderadults |